Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Although 5-year survival rates in the first-line setting range from 60% to 70%, up to 50% of patients become refractory to or relapse after treatment. Published analyses of large-scale outcome data from patient...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2017-10, Vol.130 (16), p.1800-1808
Hauptverfasser: Crump, Michael, Neelapu, Sattva S., Farooq, Umar, Van Den Neste, Eric, Kuruvilla, John, Westin, Jason, Link, Brian K., Hay, Annette, Cerhan, James R., Zhu, Liting, Boussetta, Sami, Feng, Lei, Maurer, Matthew J., Navale, Lynn, Wiezorek, Jeff, Go, William Y., Gisselbrecht, Christian
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1808
container_issue 16
container_start_page 1800
container_title Blood
container_volume 130
creator Crump, Michael
Neelapu, Sattva S.
Farooq, Umar
Van Den Neste, Eric
Kuruvilla, John
Westin, Jason
Link, Brian K.
Hay, Annette
Cerhan, James R.
Zhu, Liting
Boussetta, Sami
Feng, Lei
Maurer, Matthew J.
Navale, Lynn
Wiezorek, Jeff
Go, William Y.
Gisselbrecht, Christian
description Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Although 5-year survival rates in the first-line setting range from 60% to 70%, up to 50% of patients become refractory to or relapse after treatment. Published analyses of large-scale outcome data from patients with refractory DLBCL are limited. SCHOLAR-1, an international, multicohort retrospective non-Hodgkin lymphoma research study, retrospectively evaluated outcomes in patients with refractory DLBCL which, for this study, was defined as progressive disease or stable disease as best response at any point during chemotherapy (>4 cycles of first-line or 2 cycles of later-line therapy) or relapsed at ≤12 months from autologous stem cell transplantation. SCHOLAR-1 pooled data from 2 phase 3 clinical trials (Lymphoma Academic Research Organization-CORAL and Canadian Cancer Trials Group LY.12) and 2 observational cohorts (MD Anderson Cancer Center and University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence). Response rates and overall survival were estimated from the time of initiation of salvage therapy for refractory disease. Among 861 patients, 636 were included on the basis of refractory disease inclusion criteria. For patients with refractory DLBCL, the objective response rate was 26% (complete response rate, 7%) to the next line of therapy, and the median overall survival was 6.3 months. Twenty percent of patients were alive at 2 years. Outcomes were consistently poor across patient subgroups and study cohorts. SCHOLAR-1 is the largest patient-level pooled retrospective analysis to characterize response rates and survival for a population of patients with refractory DLBCL. •SCHOLAR-1 is the first patient-level analysis of outcomes of refractory DLBCL from 2 large randomized trials and 2 academic databases.•SCHOLAR-1 demonstrated poor outcomes in patients with refractory DLBCL, supporting a need for more effective therapies for these patients.
doi_str_mv 10.1182/blood-2017-03-769620
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5649550</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497120327786</els_id><sourcerecordid>1926681310</sourcerecordid><originalsourceid>FETCH-LOGICAL-c529t-b02426ecb5ad790c5090224737fd37143511cb6ba6ad5c0d3e5c2beaffc1ee213</originalsourceid><addsrcrecordid>eNp9kU9v1DAQxS0EokvhGyDkIxfD2InjhANSWQGttNJKFM6WY0-6Rk682E6l_fbNdkuBC6c5zHtv_vwIec3hHeeteN-HGB0TwBWDiqmmawQ8ISsuRcsABDwlKwBoWN0pfkZe5PwTgNeVkM_JmWiVqlvVrYjbzsXGETP1E004JGNLTAfq_DDMGWkw6QbpJ2YxBBoO434XR_NhUeY5lEyHFEdadri4C6bJFB8nE-j1-nK7ufjGOM1ldoeX5NlgQsZXD_Wc_Pjy-fv6km22X6_WFxtmpegK60HUokHbS-NUB1ZCB0LUqlKDq9Syu-Tc9k1vGuOkBVehtKJHMwyWIwpenZOPp9z93I_oLE4lmaD3yY8mHXQ0Xv_bmfxO38RbLZu6kxKWgLcPASn-mjEXPfp8PN1MGOeseSeapuUVP0rrk9SmmPPyuccxHPQRkL4HpI-ANFT6BGixvfl7xUfTbyJ_bsDlUbcek87W42TR-YS2aBf9_yfcAYU4pEc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1926681310</pqid></control><display><type>article</type><title>Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Crump, Michael ; Neelapu, Sattva S. ; Farooq, Umar ; Van Den Neste, Eric ; Kuruvilla, John ; Westin, Jason ; Link, Brian K. ; Hay, Annette ; Cerhan, James R. ; Zhu, Liting ; Boussetta, Sami ; Feng, Lei ; Maurer, Matthew J. ; Navale, Lynn ; Wiezorek, Jeff ; Go, William Y. ; Gisselbrecht, Christian</creator><creatorcontrib>Crump, Michael ; Neelapu, Sattva S. ; Farooq, Umar ; Van Den Neste, Eric ; Kuruvilla, John ; Westin, Jason ; Link, Brian K. ; Hay, Annette ; Cerhan, James R. ; Zhu, Liting ; Boussetta, Sami ; Feng, Lei ; Maurer, Matthew J. ; Navale, Lynn ; Wiezorek, Jeff ; Go, William Y. ; Gisselbrecht, Christian</creatorcontrib><description>Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Although 5-year survival rates in the first-line setting range from 60% to 70%, up to 50% of patients become refractory to or relapse after treatment. Published analyses of large-scale outcome data from patients with refractory DLBCL are limited. SCHOLAR-1, an international, multicohort retrospective non-Hodgkin lymphoma research study, retrospectively evaluated outcomes in patients with refractory DLBCL which, for this study, was defined as progressive disease or stable disease as best response at any point during chemotherapy (&gt;4 cycles of first-line or 2 cycles of later-line therapy) or relapsed at ≤12 months from autologous stem cell transplantation. SCHOLAR-1 pooled data from 2 phase 3 clinical trials (Lymphoma Academic Research Organization-CORAL and Canadian Cancer Trials Group LY.12) and 2 observational cohorts (MD Anderson Cancer Center and University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence). Response rates and overall survival were estimated from the time of initiation of salvage therapy for refractory disease. Among 861 patients, 636 were included on the basis of refractory disease inclusion criteria. For patients with refractory DLBCL, the objective response rate was 26% (complete response rate, 7%) to the next line of therapy, and the median overall survival was 6.3 months. Twenty percent of patients were alive at 2 years. Outcomes were consistently poor across patient subgroups and study cohorts. SCHOLAR-1 is the largest patient-level pooled retrospective analysis to characterize response rates and survival for a population of patients with refractory DLBCL. •SCHOLAR-1 is the first patient-level analysis of outcomes of refractory DLBCL from 2 large randomized trials and 2 academic databases.•SCHOLAR-1 demonstrated poor outcomes in patients with refractory DLBCL, supporting a need for more effective therapies for these patients.</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2017-03-769620</identifier><identifier>PMID: 28774879</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Clinical Trials and Observations ; Drug Resistance, Neoplasm ; Female ; Humans ; International Cooperation ; Lymphoma, Large B-Cell, Diffuse - epidemiology ; Lymphoma, Large B-Cell, Diffuse - therapy ; Male ; Middle Aged ; Multicenter Studies as Topic - statistics &amp; numerical data ; Observational Studies as Topic - statistics &amp; numerical data ; Randomized Controlled Trials as Topic - statistics &amp; numerical data ; Retrospective Studies ; Salvage Therapy ; Treatment Outcome ; Young Adult</subject><ispartof>Blood, 2017-10, Vol.130 (16), p.1800-1808</ispartof><rights>2017 American Society of Hematology</rights><rights>2017 by The American Society of Hematology.</rights><rights>2017 by The American Society of Hematology 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c529t-b02426ecb5ad790c5090224737fd37143511cb6ba6ad5c0d3e5c2beaffc1ee213</citedby><cites>FETCH-LOGICAL-c529t-b02426ecb5ad790c5090224737fd37143511cb6ba6ad5c0d3e5c2beaffc1ee213</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28774879$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Crump, Michael</creatorcontrib><creatorcontrib>Neelapu, Sattva S.</creatorcontrib><creatorcontrib>Farooq, Umar</creatorcontrib><creatorcontrib>Van Den Neste, Eric</creatorcontrib><creatorcontrib>Kuruvilla, John</creatorcontrib><creatorcontrib>Westin, Jason</creatorcontrib><creatorcontrib>Link, Brian K.</creatorcontrib><creatorcontrib>Hay, Annette</creatorcontrib><creatorcontrib>Cerhan, James R.</creatorcontrib><creatorcontrib>Zhu, Liting</creatorcontrib><creatorcontrib>Boussetta, Sami</creatorcontrib><creatorcontrib>Feng, Lei</creatorcontrib><creatorcontrib>Maurer, Matthew J.</creatorcontrib><creatorcontrib>Navale, Lynn</creatorcontrib><creatorcontrib>Wiezorek, Jeff</creatorcontrib><creatorcontrib>Go, William Y.</creatorcontrib><creatorcontrib>Gisselbrecht, Christian</creatorcontrib><title>Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study</title><title>Blood</title><addtitle>Blood</addtitle><description>Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Although 5-year survival rates in the first-line setting range from 60% to 70%, up to 50% of patients become refractory to or relapse after treatment. Published analyses of large-scale outcome data from patients with refractory DLBCL are limited. SCHOLAR-1, an international, multicohort retrospective non-Hodgkin lymphoma research study, retrospectively evaluated outcomes in patients with refractory DLBCL which, for this study, was defined as progressive disease or stable disease as best response at any point during chemotherapy (&gt;4 cycles of first-line or 2 cycles of later-line therapy) or relapsed at ≤12 months from autologous stem cell transplantation. SCHOLAR-1 pooled data from 2 phase 3 clinical trials (Lymphoma Academic Research Organization-CORAL and Canadian Cancer Trials Group LY.12) and 2 observational cohorts (MD Anderson Cancer Center and University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence). Response rates and overall survival were estimated from the time of initiation of salvage therapy for refractory disease. Among 861 patients, 636 were included on the basis of refractory disease inclusion criteria. For patients with refractory DLBCL, the objective response rate was 26% (complete response rate, 7%) to the next line of therapy, and the median overall survival was 6.3 months. Twenty percent of patients were alive at 2 years. Outcomes were consistently poor across patient subgroups and study cohorts. SCHOLAR-1 is the largest patient-level pooled retrospective analysis to characterize response rates and survival for a population of patients with refractory DLBCL. •SCHOLAR-1 is the first patient-level analysis of outcomes of refractory DLBCL from 2 large randomized trials and 2 academic databases.•SCHOLAR-1 demonstrated poor outcomes in patients with refractory DLBCL, supporting a need for more effective therapies for these patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Clinical Trials and Observations</subject><subject>Drug Resistance, Neoplasm</subject><subject>Female</subject><subject>Humans</subject><subject>International Cooperation</subject><subject>Lymphoma, Large B-Cell, Diffuse - epidemiology</subject><subject>Lymphoma, Large B-Cell, Diffuse - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multicenter Studies as Topic - statistics &amp; numerical data</subject><subject>Observational Studies as Topic - statistics &amp; numerical data</subject><subject>Randomized Controlled Trials as Topic - statistics &amp; numerical data</subject><subject>Retrospective Studies</subject><subject>Salvage Therapy</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU9v1DAQxS0EokvhGyDkIxfD2InjhANSWQGttNJKFM6WY0-6Rk682E6l_fbNdkuBC6c5zHtv_vwIec3hHeeteN-HGB0TwBWDiqmmawQ8ISsuRcsABDwlKwBoWN0pfkZe5PwTgNeVkM_JmWiVqlvVrYjbzsXGETP1E004JGNLTAfq_DDMGWkw6QbpJ2YxBBoO434XR_NhUeY5lEyHFEdadri4C6bJFB8nE-j1-nK7ufjGOM1ldoeX5NlgQsZXD_Wc_Pjy-fv6km22X6_WFxtmpegK60HUokHbS-NUB1ZCB0LUqlKDq9Syu-Tc9k1vGuOkBVehtKJHMwyWIwpenZOPp9z93I_oLE4lmaD3yY8mHXQ0Xv_bmfxO38RbLZu6kxKWgLcPASn-mjEXPfp8PN1MGOeseSeapuUVP0rrk9SmmPPyuccxHPQRkL4HpI-ANFT6BGixvfl7xUfTbyJ_bsDlUbcek87W42TR-YS2aBf9_yfcAYU4pEc</recordid><startdate>20171019</startdate><enddate>20171019</enddate><creator>Crump, Michael</creator><creator>Neelapu, Sattva S.</creator><creator>Farooq, Umar</creator><creator>Van Den Neste, Eric</creator><creator>Kuruvilla, John</creator><creator>Westin, Jason</creator><creator>Link, Brian K.</creator><creator>Hay, Annette</creator><creator>Cerhan, James R.</creator><creator>Zhu, Liting</creator><creator>Boussetta, Sami</creator><creator>Feng, Lei</creator><creator>Maurer, Matthew J.</creator><creator>Navale, Lynn</creator><creator>Wiezorek, Jeff</creator><creator>Go, William Y.</creator><creator>Gisselbrecht, Christian</creator><general>Elsevier Inc</general><general>American Society of Hematology</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20171019</creationdate><title>Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study</title><author>Crump, Michael ; Neelapu, Sattva S. ; Farooq, Umar ; Van Den Neste, Eric ; Kuruvilla, John ; Westin, Jason ; Link, Brian K. ; Hay, Annette ; Cerhan, James R. ; Zhu, Liting ; Boussetta, Sami ; Feng, Lei ; Maurer, Matthew J. ; Navale, Lynn ; Wiezorek, Jeff ; Go, William Y. ; Gisselbrecht, Christian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c529t-b02426ecb5ad790c5090224737fd37143511cb6ba6ad5c0d3e5c2beaffc1ee213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Clinical Trials and Observations</topic><topic>Drug Resistance, Neoplasm</topic><topic>Female</topic><topic>Humans</topic><topic>International Cooperation</topic><topic>Lymphoma, Large B-Cell, Diffuse - epidemiology</topic><topic>Lymphoma, Large B-Cell, Diffuse - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multicenter Studies as Topic - statistics &amp; numerical data</topic><topic>Observational Studies as Topic - statistics &amp; numerical data</topic><topic>Randomized Controlled Trials as Topic - statistics &amp; numerical data</topic><topic>Retrospective Studies</topic><topic>Salvage Therapy</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Crump, Michael</creatorcontrib><creatorcontrib>Neelapu, Sattva S.</creatorcontrib><creatorcontrib>Farooq, Umar</creatorcontrib><creatorcontrib>Van Den Neste, Eric</creatorcontrib><creatorcontrib>Kuruvilla, John</creatorcontrib><creatorcontrib>Westin, Jason</creatorcontrib><creatorcontrib>Link, Brian K.</creatorcontrib><creatorcontrib>Hay, Annette</creatorcontrib><creatorcontrib>Cerhan, James R.</creatorcontrib><creatorcontrib>Zhu, Liting</creatorcontrib><creatorcontrib>Boussetta, Sami</creatorcontrib><creatorcontrib>Feng, Lei</creatorcontrib><creatorcontrib>Maurer, Matthew J.</creatorcontrib><creatorcontrib>Navale, Lynn</creatorcontrib><creatorcontrib>Wiezorek, Jeff</creatorcontrib><creatorcontrib>Go, William Y.</creatorcontrib><creatorcontrib>Gisselbrecht, Christian</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Crump, Michael</au><au>Neelapu, Sattva S.</au><au>Farooq, Umar</au><au>Van Den Neste, Eric</au><au>Kuruvilla, John</au><au>Westin, Jason</au><au>Link, Brian K.</au><au>Hay, Annette</au><au>Cerhan, James R.</au><au>Zhu, Liting</au><au>Boussetta, Sami</au><au>Feng, Lei</au><au>Maurer, Matthew J.</au><au>Navale, Lynn</au><au>Wiezorek, Jeff</au><au>Go, William Y.</au><au>Gisselbrecht, Christian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>2017-10-19</date><risdate>2017</risdate><volume>130</volume><issue>16</issue><spage>1800</spage><epage>1808</epage><pages>1800-1808</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Although 5-year survival rates in the first-line setting range from 60% to 70%, up to 50% of patients become refractory to or relapse after treatment. Published analyses of large-scale outcome data from patients with refractory DLBCL are limited. SCHOLAR-1, an international, multicohort retrospective non-Hodgkin lymphoma research study, retrospectively evaluated outcomes in patients with refractory DLBCL which, for this study, was defined as progressive disease or stable disease as best response at any point during chemotherapy (&gt;4 cycles of first-line or 2 cycles of later-line therapy) or relapsed at ≤12 months from autologous stem cell transplantation. SCHOLAR-1 pooled data from 2 phase 3 clinical trials (Lymphoma Academic Research Organization-CORAL and Canadian Cancer Trials Group LY.12) and 2 observational cohorts (MD Anderson Cancer Center and University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence). Response rates and overall survival were estimated from the time of initiation of salvage therapy for refractory disease. Among 861 patients, 636 were included on the basis of refractory disease inclusion criteria. For patients with refractory DLBCL, the objective response rate was 26% (complete response rate, 7%) to the next line of therapy, and the median overall survival was 6.3 months. Twenty percent of patients were alive at 2 years. Outcomes were consistently poor across patient subgroups and study cohorts. SCHOLAR-1 is the largest patient-level pooled retrospective analysis to characterize response rates and survival for a population of patients with refractory DLBCL. •SCHOLAR-1 is the first patient-level analysis of outcomes of refractory DLBCL from 2 large randomized trials and 2 academic databases.•SCHOLAR-1 demonstrated poor outcomes in patients with refractory DLBCL, supporting a need for more effective therapies for these patients.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28774879</pmid><doi>10.1182/blood-2017-03-769620</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 2017-10, Vol.130 (16), p.1800-1808
issn 0006-4971
1528-0020
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5649550
source MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Adult
Aged
Aged, 80 and over
Clinical Trials and Observations
Drug Resistance, Neoplasm
Female
Humans
International Cooperation
Lymphoma, Large B-Cell, Diffuse - epidemiology
Lymphoma, Large B-Cell, Diffuse - therapy
Male
Middle Aged
Multicenter Studies as Topic - statistics & numerical data
Observational Studies as Topic - statistics & numerical data
Randomized Controlled Trials as Topic - statistics & numerical data
Retrospective Studies
Salvage Therapy
Treatment Outcome
Young Adult
title Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T19%3A49%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcomes%20in%20refractory%20diffuse%20large%20B-cell%20lymphoma:%20results%20from%20the%20international%20SCHOLAR-1%20study&rft.jtitle=Blood&rft.au=Crump,%20Michael&rft.date=2017-10-19&rft.volume=130&rft.issue=16&rft.spage=1800&rft.epage=1808&rft.pages=1800-1808&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2017-03-769620&rft_dat=%3Cproquest_pubme%3E1926681310%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1926681310&rft_id=info:pmid/28774879&rft_els_id=S0006497120327786&rfr_iscdi=true